Clinical Characteristics and Outcomes of a High-grade Endometrial Cancer Cohort Treated at Instituto Nacional de Câncer, Brazil.

Características clínicas e desfechos de uma coorte de câncer endometrial de alto grau tratada no Instituto Nacional de Câncer, Brasil.

Publisher: Thieme Medical Publishers Country of Publication: Brazil NLM ID: 9214757 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1806-9339 (Electronic) Linking ISSN: 01007203 NLM ISO Abbreviation: Rev Bras Ginecol Obstet Subsets: MEDLINE

Publication: <2016- > : São Paulo, Brazil : Thieme Medical Publishers
Original Publication: [São Paulo, Brazil] : Medisa Editora

Endometrial Neoplasms*/epidemiology ; Endometrial Neoplasms*/therapy ; Carcinosarcoma* ; Cystadenocarcinoma, Serous*; Female ; Pregnancy ; Humans ; Aged ; Middle Aged ; Brazil/epidemiology ; Endometrium

Objective:  To analyze the outcomes of a cohort of patients with high-risk histologies of endometrial cancer (EC) treated at Instituto Nacional de Câncer (National Cancer Institute, INCA, in Portuguese), in Brazil.
Materials and Methods:  We reviewed the medical records of patients with high-risk histologies of EC in any stage registered at INCA between 2010 and 2016 to perform a clinical and demographic descriptive analysis and to evaluate the outcomes in terms of recurrence and survival.
Results:  From 2010 to 2016, 2,145 EC patients were registered and treated at INCA, and 466 had high-grade histologies that met the inclusion criteria. The mean age of the patients was 65 years, 44.6% were Caucasian, and 90% had a performance status of 0 or 1. The most common histology was high-grade endometrioid (31.1%), followed by serous carcinoma (25.3%), mixed (20.0%), carcinosarcoma (13.5%), and clear cell carcinoma (9.4%). Considering the 2018 Fédération Internationale de Gynécologie et d'Obstétrique (International Federation of Gynecology and Obstetrics, FIGO, in French) staging system, 44.8%, 12.4%, 29.8%, and 12.9% of the patient were in stages I, II, III or IV respectively. Age (> 60 years), more than 50% of myoinvasion, higher stage, poor performance status, serous and carcinosarcoma histologies, and adjuvant treatment were independent factors associated with recurrence-free survival (RFS) and overall survival (OS) in the multivariate analysis.
Conclusion:  The current findings reinforced the international data showing poor outcomes of these tumors, especially for serous and carcinosarcomas and tumors with advanced stages, with shorter survival and high recurrence rates in distant sites, independently of the FIGO stage. Adjuvant therapy was associated with better survival.
Competing Interests: The authors have no conflict of interests to declare.
(Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/).)

J Clin Oncol. 2012 Mar 1;30(7):695-700. (PMID: 22291074)
Gynecol Oncol. 2016 Dec;143(3):460-465. (PMID: 27743738)
Ann Oncol. 2022 Sep;33(9):860-877. (PMID: 35690222)
Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):79-85. (PMID: 12182977)
JAMA. 2017 Mar 28;317(12):1224-1233. (PMID: 28350928)
Gynecol Oncol. 2013 Dec;131(3):512-9. (PMID: 24103471)
Nature. 2013 May 2;497(7447):67-73. (PMID: 23636398)
Gynecol Oncol. 1983 Feb;15(1):10-7. (PMID: 6822361)
Rev Bras Ginecol Obstet. 2018 Oct;40(10):577-579. (PMID: 30352454)
Int J Gynecol Cancer. 2021 Jan;31(1):12-39. (PMID: 33397713)
Int J Gynecol Cancer. 2011 May;21(4):661-7. (PMID: 21412164)
Gynecol Oncol. 2015 Nov;139(2):268-74. (PMID: 26352641)
Gynecol Oncol. 2013 Jun;129(3):478-85. (PMID: 23535279)
Lancet. 1993 Nov 27;342(8883):1317-22. (PMID: 7901634)

Local Abstract: [Publisher, Portuguese]  Analisar os desfechos de uma coorte de pacientes com câncer de endométrio (CE) e histologias de alto risco atendida no Instituto Nacional do Câncer (INCA) entre 2010 e 2016. MATERIAIS E MéTODOS:  Foram revisados prontuários de pacientes com histologias de alto risco de CE em qualquer estágio cadastradas no INCA entre 2010 e 2016 para realizar uma análise descritiva clínica e demográfica e avaliar os resultados em termos de recorrência e sobrevida. [Publisher, Portuguese]  De 2010 a 2016, 2.145 pacientes com CE foram cadastradas e atendidas no INCA, e 466 tinham histologias de alto grau e atendiam aos critérios de inclusão. A média de idade das pacientes foi de 65 anos, 44,6% eram brancas, e 90% tinham performance status de 0 ou 1. A histologia mais comum foi endometrioide de alto grau (31,1%), seguida de carcinoma seroso (25,3%), misto (20,0%), carcinossarcoma (13,5%) e carcinoma de células claras (9,4%). Considerando o estadiamento da Fédération Internationale de Gynécologie et d'Obstétrique (Federação Internacional de Ginecologia e Obstetrícia, FIGO, em francês) de 2018, 44,8%, 12,4%, 29,8% e 12,9% apresentaram estágios I, II, III ou IV, respectivamente. Idade (> 60 anos), mais de 50% de mioinvasão, estágio avançado, performance status ruim, histologias serosas e carcinossarcoma, e tratamento adjuvante foram fatores independentes associados à sobrevida livre de recorrência e sobrevida global na análise multivariada. CONCLUSãO:  Os achados atuais reforçam os dados internacionais que demonstram o prognóstico ruim desses tumores, principalmente para as histologias serosas e carcinossarcomas e para estágios avançados, com menor sobrevida e altas taxas de recorrência à distância, independentemente do estágio da FIGO. A terapia adjuvante foi associada a melhor sobrevida.

Date Created: 20230818 Date Completed: 20230821 Latest Revision: 20230823

20231215

PMC10438965

10.1055/s-0043-1772177

37595597